Mayo Clinic Tapestry 2.0: Applying Multi-Omics for Scientific Discovery

NCT06456320 | Enrolling By Invitation

• 1 other identifier: 23-004120
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this study is to use multi-omics testing on samples collected from Mayo Clinic patients to build and expand on what has been learned about genomic data.

Conditions

Genetic Predisposition; Exposure, Environmental

Outcome Measures

Primary Outcomes (1)

• Creation of a unique integrated asset of multi-omics data

  A variety of patient cohorts will be ascertained throughout this study. Data will be made available to researchers to query correlations of disease states and clinical outcomes to multi-omics findings. These insights will be invaluable to creating omics-informed care plans in the future. Standard descriptive statistics approaches will be used for analysis.

  Up to 5 years

Study Arms (2)

Suspected Genetic Predisposition or Multi-Omics Contribution

Patients with a diagnosis or phenotype with the potential for association with a genetic predisposition or Multi-Omics Contribution.

Healthy Control

Patients with no diagnosis associated with a genetic predisposition or Multi-Omics Contribution.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Mayo Clinic patients

You may qualify if:

• Age ≥ 18 years
• Registered Mayo Clinic patient
• Able to provide informed written consent
• Able to receive mail and packages within a United States (US) state
• Able to collect and ship samples within a US state

You may not qualify if:

• Active hematological cancer or history of a hematological cancer
• Allogeneic Bone Marrow Transplant (e.g., samples from autologous bone marrow transplant recipients are acceptable if collected at least one month after transplant)
• Other co-morbidity that, in physician's opinion, would interfere with patient's ability to participate in the study (e.g., reduced ability to comprehend, i.e., dementia, intellectual disability, etc.)

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (3)

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States

Location

Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States

Location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Stool, urine, saliva, plasma, white blood cells (WBC), peripheral blood mononuclear cells (PBMC), whole blood

MeSH Terms

Conditions

Genetic Predisposition to Disease

Condition Hierarchy (Ancestors)

Disease Susceptibility; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Konstantinos N. Lazaridis, M.D.

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Executive Director, Center for Individualized Medicine

Study Record Dates

• First Submitted: June 7, 2024
• First Posted: June 13, 2024
• Study Start: September 5, 2024
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: October 16, 2025

Record last verified: 2025-09

Locations

US (3)